Article | March 9, 2021

Optimize Bioprocessing Efficiency With A Standardized Automation Platform For DeltaV

Source: Cytiva

By Jeremy Bezaire, Product Manager, Cytiva

Aug 06 2018 - GE Healthcare - 0062d-feature

Due to the inherent variability and complexity in bioprocessing, FDA approval of a biologic drug product is heavily dependent on the agency’s confidence in quality control during the manufacturing process. Combined with considerable growth and opportunity in the biologics market, this has led to an increased focus on adopting technologies that can help ensure consistency and repeatability during manufacturing.

Automation is often a key component in these solutions, since minimizing manual interactions and optimizing the flow of data can lead to greater levels of efficiency and speed/control across the entire biomanufacturing life cycle. As you integrate automation in a biomanufacturing facility, you may consider either equipment level automation (i.e., islands of automation) or a comprehensive, distributed control system (DCS) to realize integration and control capabilities.  Choosing the right option for your company will depend on where you are in your digital plant maturation process and where you want to get to in the future. A Cytiva Figurate™ automation solution built upon a DeltaV™ DCS platform will simplify engineering management, improve data management, reduce process risk, and ensure that you have the ability to grow your automation system with your company needs.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development